2020
DOI: 10.1159/000510936
|View full text |Cite
|
Sign up to set email alerts
|

Breast Metastasis from Neuroendocrine Carcinoma of the Lung: A Case Report and Review of the Literature

Abstract: Breast metastasis originating from non-mammary tumors is an uncommon event accounting for 0.5–6.6% of all breast neoplasms. The primary malignancies that reportedly metastasize to the breast most frequently are hematologic malignancies, such as leukemia and lymphoma and malignant melanoma. Breast cancer metastasis resulting from a primary lung neoplasm is significantly less commonly described in the literature. Herein, we present the unusual case of a patient with metastatic disease to the breast from a primar… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 17 publications
0
1
0
Order By: Relevance
“…SLCS is an aggressive neuroendocrine tumor that exceptionally metastasizes to the breast (0.2%-1.3%) [1,5]. Pulmonary SLCS is often diagnosed incidentally, given its insidious nature [2,6]. There are only two cases of bilateral breast metastases from pulmonary SLCS in male patients reported in the literature in 1976 and 2011 [7,3].…”
Section: Discussionmentioning
confidence: 99%
“…SLCS is an aggressive neuroendocrine tumor that exceptionally metastasizes to the breast (0.2%-1.3%) [1,5]. Pulmonary SLCS is often diagnosed incidentally, given its insidious nature [2,6]. There are only two cases of bilateral breast metastases from pulmonary SLCS in male patients reported in the literature in 1976 and 2011 [7,3].…”
Section: Discussionmentioning
confidence: 99%
“…Approximately 70% of the patients with SCLC already have metastasis at diagnosis. Despite being a common and aggressive tumor with a tendency to metastasize, breast involvement is surprisingly rare [ [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] ]. The prognosis is abysmal whether one or both breasts are involved by SCLC, with an estimated five-year survival of only 2% [ 13 ].…”
Section: Discussionmentioning
confidence: 99%